Can machines learn to discover drugs? Take the right dataset, add an ingenious algorithm or two – and voilá! Your billion-euro blockbuster molecule is ready! AI-driven drug development is exciting investor interest, while Big Pharma is … more ➔
The great green rush It’s the most commonly cultivated, trafficked and abused illicit drug worldwide, and there’s still a lot of social stigma attached to the recreational use of pot. But it’s slowly dawning on regulators … more ➔
CJEU ruling triggers exodus of EU plant... According to a brand-new EU-wide survey, European plant researchers are concerned about the European Court of Justices (CJEU) interpretation that targeted mutation methods aimed at improving crop … more ➔
Highest manufacturing standard: First Line Datwyler Sealing Solutions is a leading industrial supplier and a key player in the global health care world. Our unique product range includes the most advanced elastomer formulations, coatings, aluminum … more ➔
Endothelial disruption: From bench to be...Bio-ADM, the very first blood biomarker capable to diagnose when blood vessels become leaky (endothelial dysfunction), is set to make a rapid carrier at intensive care units (ICUs) and emergency departments … more ➔
Are novel antibiotics worth investing in? In autumn, stakeholders across the globe pledged to take more action in the fight against antimicrobial resistance (AMR). Whereas from the push side new public and private initiatives appeared on the … more ➔
Closing a gap at ICUsDiagnostic results must be readily available to diagnose critically ill patients in emergency settings and at ICUs. So far, diagnostic blood tests, which demonstrably could help emergency meds recognise … more ➔
Vertical integration: time is moneyFinancial pressure on Big Pharma and biotechs increases the need for drug developers to outsource their development and manufacturing capabilities. The CDMO and CRO sector, which is further consolidating … more ➔
CARs right on trackSince reports that blood cancer response rates to T cells carrying chimeric antigen receptors (CARs) exceed 80%, investors have been laying bets on CAR-T cell approaches. In August, the first two therapies … more ➔
Fully human antibodies for advanced immu...Answering the increasing demand for novel fully human antibodies in immunotherapy, German biotech pioneer YUMAB GmbH accelerates drug discovery and development with a comprehensive and versatile technology … more ➔
![Reference [1]?Schafer, S. et al. Nature 552, 110115 (2017)](https://european-biotechnology.com/wp-content/uploads/2024/04/EB_Autumn_2018_YUMAB-300x169.jpg "EB_Autumn_2018_YUMAB.jpg")
